Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $31.83

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $31.8333.

Several brokerages have commented on STRO. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Wedbush reissued a “neutral” rating and issued a $100.00 price objective (up previously from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Finally, Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price on the stock in a research note on Tuesday, January 20th.

Institutional Investors Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently modified their holdings of STRO. State of Tennessee Department of Treasury acquired a new position in shares of Sutro Biopharma in the 4th quarter valued at approximately $86,000. Jane Street Group LLC acquired a new stake in shares of Sutro Biopharma in the 4th quarter valued at about $265,000. CWM LLC raised its stake in shares of Sutro Biopharma by 73.2% in the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after purchasing an additional 23,941 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Catalyst Funds Management Pty Ltd acquired a new position in Sutro Biopharma in the second quarter worth about $27,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Down 0.1%

Shares of STRO opened at $18.40 on Friday. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $19.90. The company’s fifty day moving average is $13.60 and its two-hundred day moving average is $10.69. The firm has a market cap of $156.58 million, a PE ratio of -0.70 and a beta of 1.54.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.